Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy

Abstract

Congenital heart disease (CHD) is the most common inborn defect, affecting approximately 1% of all newborns worldwide. Advances in its diagnosis and treatment have led to dramatic improvements in patients' quality of life and long-term survival. Nevertheless, despite these innovations many patients require life-long follow-up and are at risk of numerous complications, namely, residual or progressive hemodynamic lesions, arrhythmia, sudden cardiac death, and the development of heart failure and pulmonary arterial hypertension (PAH), despite timely surgical intervention. Ill advisedly, some patients are also lost to follow-up, assuming that their early life surgical or catheter-based intervention was curative, hence missing out on invaluable lifetime screening and timely interventions that may be necessary. Additionally, there are many patients with undiagnosed or unoperated CHD in the developing world presenting later in life with irreversible complications. Even in this modern era of diagnosis and screening, PAH-CHD remains a burden in patients with CHD, with approximations of up to 10% in this heterogeneous group and is associated with an adverse impact on quality of life and survival.

Keywords

congenital heart disease - Eisenmenger's syndrome - pulmonary arterial hypertension - Down's syndrome - Fontan circulation - left-to-right shunt

• References

• 1 van der Linde D, Konings EE, Slager MA. , et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58 (21) 2241-2247
• 2 Warnes CA, Williams RG, Bashore TM. , et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118 (23) e714-e833
• 3 Engelfriet PM, Duffels MG, Möller T. , et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93 (06) 682-687
• 4 Duffels MG, Engelfriet PM, Berger RM. , et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120 (02) 198-204
• 5 Engelfriet P, Boersma E, Oechslin E. , et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26 (21) 2325-2333
• 6 Saha A, Balakrishnan KG, Jaiswal PK. , et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994; 45 (03) 199-207
• 7 Moceri P, Kempny A, Liodakis E. , et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol 2015; 179: 455-460
• 8 Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT. , et al; REHAP Investigators. Pulmonary hypertension and congenital heart disease: an insight from the REHAP National Registry. Int J Cardiol 2015; 184: 717-723
• 9 Galie N, Manes A, Palazzini M. , et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008; 68 (08) 1049-1066
• 10 Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115 (08) 1039-1050
• 11 Dimopoulos K, Giannakoulas G, Wort SJ, Gatzoulis MA. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 2008; 23 (06) 545-554
• 12 Daliento L, Somerville J, Presbitero P. , et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19 (12) 1845-1855
• 13 Diller GP, Dimopoulos K, Broberg CS. , et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27 (14) 1737-1742
• 14 Kidd L, Driscoll DJ, Gersony WM. , et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87 (2, Suppl): I38-I51
• 15 Simonneau G, Gatzoulis MA, Adatia I. , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D34-D41
• 16 Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58 (05) 538-546
• 17 Ramjug S, Hussain N, Hurdman J. , et al. Pulmonary arterial hypertension associated with congenital heart disease: comparison of clinical and anatomic-pathophysiologic classification. J Heart Lung Transplant 2016; 35 (05) 610-618
• 18 Kempny A, Hjortshøj CS, Gu H. , et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicenter study. Circulation 2017; 135 (15) 1432-1440
• 19 Haworth SG. Pulmonary hypertension in the young. Heart 2002; 88 (06) 658-664
• 20 Balint OH, Samman A, Haberer K. , et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart 2008; 94 (09) 1189-1193
• 21 Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014; 35 (11) 691-700
• 22 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
• 23 Lopes AA, O'Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009; 19 (05) 431-435
• 24 Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008; 129 (02) 163-171
• 25 Myers PO, Tissot C, Beghetti M. Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. Circ J 2014; 78 (01) 4-11
• 26 Smadja DM, Gaussem P, Mauge L. , et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009; 119 (03) 374-381
• 27 Wei C, Henderson H, Spradley C. , et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One 2013; 8 (05) e64396
• 28 Dimopoulos K, Diller GP, Petraco R. , et al. Hyponatraemia: a strong predictor of mortality in adults with congenital heart disease. Eur Heart J 2010; 31 (05) 595-601
• 29 Dimopoulos K, Okonko DO, Diller GP. , et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006; 113 (24) 2796-2802
• 30 Dimopoulos K, Diller GP, Koltsida E. , et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 2008; 117 (18) 2320-2328
• 31 Alonso-Gonzalez R, Borgia F, Diller GP. , et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation 2013; 127 (08) 882-890
• 32 Scognamiglio G, Kempny A, Price LC. , et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart 2014; 100 (17) 1335-1341
• 33 Kempny A, Diller GP, Alonso-Gonzalez R. , et al. Hypoalbuminaemia predicts outcome in adult patients with congenital heart disease. Heart 2015; 101 (09) 699-705
• 34 Oechslin E, Mebus S, Schulze-Neick I. , et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point Part III: Specific management and surgical aspects. Curr Cardiol Rev 2010; 6 (04) 363-372
• 35 Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol 2004; 97 (Suppl. 01) 109-115
• 36 Silversides CK, Salehian O, Oechslin E. , et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions. Can J Cardiol 2010; 26 (03) e98-e117
• 37 Broberg CS, Bax BE, Okonko DO. , et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48 (02) 356-365
• 38 Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993; 87 (06) 1954-1959
• 39 Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28 (03) 768-772
• 40 Linderkamp O, Klose HJ, Betke K. , et al. Increased blood viscosity in patients with cyanotic congenital heart disease and iron deficiency. J Pediatr 1979; 95 (04) 567-569
• 41 Hoffmann A, Chockalingam P, Balint OH. , et al. Cerebrovascular accidents in adult patients with congenital heart disease. Heart 2010; 96 (15) 1223-1226
• 42 Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am J Cardiol 2006; 98 (02) 254-258
• 43 Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 1988; 109 (05) 406-413
• 44 Dimopoulos K, Giannakoulas G, Bendayan I. , et al. Cardiothoracic ratio from postero-anterior chest radiographs: a simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease. Int J Cardiol 2013; 166 (02) 453-457
• 45 Rasciti E, Sverzellati N, Silva M. , et al. Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension. Radiol Med (Torino) 2017; 122 (04) 257-264
• 46 Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42 (11) 1982-1987
• 47 Broberg CS, Ujita M, Prasad S. , et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007; 50 (07) 634-642
• 48 Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92 (02) 182-187
• 49 Van De Bruaene A, Delcroix M, Pasquet A. , et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011; 32 (22) 2790-2799
• 50 Tay EL, Peset A, Papaphylactou M. , et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011; 151 (03) 307-312
• 51 Spence MS, Balaratnam MS, Gatzoulis MA. Clinical update: cyanotic adult congenital heart disease. Lancet 2007; 370 (9598): 1530-1532
• 52 Anker SD, Comin Colet J, Filippatos G. , et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361 (25) 2436-2448
• 53 Kaemmerer H, Fratz S, Braun SL. , et al. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol 2004; 94 (06) 825-828
• 54 Suedekum NA, Dimeff RJ. Iron and the athlete. Curr Sports Med Rep 2005; 4 (04) 199-202
• 55 McLane JA, Fell RD, McKay RH, Winder WW, Brown EB, Holloszy JO. Physiological and biochemical effects of iron deficiency on rat skeletal muscle. Am J Physiol 1981; 241 (01) C47-C54
• 56 Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120 (05) 1547-1555
• 57 Sandoval J, Aguirre JS, Pulido T. , et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164 (09) 1682-1687
• 58 Harinck E, Hutter PA, Hoorntje TM. , et al. Air travel and adults with cyanotic congenital heart disease. Circulation 1996; 93 (02) 272-276
• 59 Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG, Gatzoulis MA. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart 2007; 93 (12) 1599-1603
• 60 Ross EA, Perloff JK, Danovitch GM, Child JS, Canobbio MM. Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. Circulation 1986; 73 (03) 396-400
• 61 Oya H, Nagaya N, Satoh T. , et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000; 84 (01) 53-58
• 62 Diller GP, Kempny A, Inuzuka R. , et al. Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart 2014; 100 (17) 1366-1372
• 63 Diller GP, Körten MA, Bauer UM. , et al; German Competence Network for Congenital Heart Defects Investigators. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J 2016; 37 (18) 1449-1455
• 64 Dimopoulos K, Inuzuka R, Goletto S. , et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121 (01) 20-25
• 65 Mebus S, Schulze-Neick I, Oechslin E. , et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point Part II: Medical treatment - study results. Curr Cardiol Rev 2010; 6 (04) 356-362
• 66 D'Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart 2014; 100 (17) 1322-1328
• 67 Galiè N, Beghetti M, Gatzoulis MA. , et al; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114 (01) 48-54
• 68 Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011; 6 (05) 424-431
• 69 Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31 (09) 1124-1131
• 70 Moceri P, Dimopoulos K, Liodakis E. , et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation 2012; 126 (12) 1461-1468
• 71 Cacoub P, Dorent R, Maistre G. , et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993; 71 (05) 448-450
• 72 Gatzoulis MA, Beghetti M, Galiè N. , et al; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127 (01) 27-32
• 73 Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011; 107 (09) 1381-1385
• 74 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
• 75 Gatzoulis MA. . A multi-center, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger syndrome. Clinicaltrials.gov reference number NCT01743001
• 76 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351 (14) 1425-1436
• 77 Galiè N, Humbert M, Vachiery JL. , et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. Kardiol Pol 2015; 73 (12) 1127-1206
• 78 Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151 (04) 851.e1-851.e5
• 79 Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120 (03) 301-305
• 80 Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 2007; 120 (03) 306-313
• 81 Ghofrani HA, Galiè N, Grimminger F. , et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 330-340
• 82 Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 2015; 45 (05) 1314-1322
• 83 Rosenkranz S, Ghofrani HA, Beghetti M. , et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015; 101 (22) 1792-1799
• 84 Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48 (05) 890-896
• 85 McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106 (12) 1477-1482
• 86 Galiè N, Humbert M, Vachiéry JL. , et al; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39 (09) 1496-1502
• 87 Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S): 81S-88S
• 88 Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99 (14) 1858-1865
• 89 Fernandes SM, Newburger JW, Lang P. , et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003; 91 (05) 632-635
• 90 Badesch DB, McLaughlin VV, Delcroix M. , et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S): 56S-61S
• 91 Olschewski H, Simonneau G, Galiè N. , et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (05) 322-329
• 92 Simonneau G, Barst RJ, Galie N. , et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (06) 800-804
• 93 Tapson VF, Gomberg-Maitland M, McLaughlin VV. , et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129 (03) 683-688
• 94 Lang I, Gomez-Sanchez M, Kneussl M. , et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129 (06) 1636-1643
• 95 Jing ZC, Parikh K, Pulido T. , et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127 (05) 624-633
• 96 Tapson VF, Torres F, Kermeen F. , et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142 (06) 1383-1390
• 97 Simonneau G, Torbicki A, Hoeper MM. , et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40 (04) 874-880
• 98 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373 (26) 2522-2533
• 99 Galiè N, Rubin Lj, Hoeper M. , et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371 (9630): 2093-2100
• 100 Sitbon O, Sattler C, Bertoletti L. , et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47 (06) 1727-1736
• 101 D'Alto M, Romeo E, Argiento P. , et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012; 155 (03) 378-382
• 102 Hascoët S, Baruteau AE, Humbert M. , et al. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. J Heart Lung Transplant 2017; 36 (04) 386-398
• 103 Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21 (07) 731-737
• 104 Stoica SC, Perreas K, Sharples LD. , et al. Heart-lung transplantation for Eisenmenger's syndrome: operative risks and late outcomes of 51 consecutive cases from a single institution. J Heart Lung Transplant 2001; 20 (02) 173-174
• 105 Christie JD, Edwards LB, Kucheryavaya AY. , et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant 2010; 29 (10) 1104-1118
• 106 McLaughlin VV, Archer SL, Badesch DB. , et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16) 2250-2294
• 107 Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol 1999; 33 (01) 222-227
• 108 Bennett JM, Ehrenfeld JM, Markham L, Eagle SS. Anesthetic management and outcomes for patients with pulmonary hypertension and intracardiac shunts and Eisenmenger syndrome: a review of institutional experience. J Clin Anesth 2014; 26 (04) 286-293
• 109 Habib G, Lancellotti P, Antunes MJ. , et al; Document Reviewers. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36 (44) 3075-3128
• 110 Gleicher N, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol Surv 1979; 34 (10) 721-741
• 111 Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31 (07) 1650-1657
• 112 Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J 2009; 30 (03) 256-265
• 113 Ladouceur M, Benoit L, Radojevic J. , et al. Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease. Heart 2017; 103 (04) 287-292
• 114 Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary hypertension. Neth Heart J 2011; 19 (12) 504-508
• 115 Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006; 92 (10) 1520-1525
• 116 Soma-Pillay P, Nene Z, Mathivha TM, Macdonald AP. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstet Med 2011; 4 (01) 24-27
• 117 Drenthen W, Pieper PG, Roos-Hesselink JW. , et al; ZAHARA Investigators. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49 (24) 2303-2311
• 118 Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33 (06) 1637-1641
• 119 Kiely DG, Condliffe R, Webster V. , et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010; 117 (05) 565-574
• 120 Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C. , et al; European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM); ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (24) 3147-3197
• 121 Freeman SB, Bean LH, Allen EG. , et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med 2008; 10 (03) 173-180
• 122 Cua CL, Rogers LK, Chicoine LG. , et al. Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine. Eur J Pediatr 2011; 170 (07) 859-863
• 123 Cappelli-Bigazzi M, Santoro G, Battaglia C. , et al. Endothelial cell function in patients with Down's syndrome. Am J Cardiol 2004; 94 (03) 392-395
• 124 Duffels MG, Vis JC, van Loon RL. , et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option?. Int J Cardiol 2009; 134 (03) 378-383
• 125 Dimopoulos K, Kempny A. Patients with Down syndrome and congenital heart disease: survival is improving, but challenges remain. Heart 2016; 102 (19) 1515-1517
• 126 Schuuring MJ, Bouma BJ, Cordina R. , et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol 2013; 164 (01) 106-110
• 127 Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971; 26 (03) 240-248
• 128 Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29 (13) 1681-1687
• 129 Goldberg DJ, French B, McBride MG. , et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123 (11) 1185-1193
• 130 Schuuring MJ, Vis JC, van Dijk AP. , et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013; 15 (06) 690-698
• 131 Hebert A, Mikkelsen UR, Thilen U. , et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation 2014; 130 (23) 2021-2030